Company intelligence / Profile preview

Neurophet

Ownership: Private
Development stage: Commercial

Overview

Neurophet has achieved commercial deployment of its AI-driven brain imaging analysis solutions. Its flagship products have received regulatory clearances such as US FDA 510(k) for use in supporting diagnosis, monitoring treatment efficacy/side effects of Alzheimer’s therapies, and guiding neuromodulation treatments. The company is actively partnering with global pharmaceutical companies to support clinical trials—especially those targeting Alzheimer’s disease—with its Imaging CRO services.

Therapeutic areas: Neurology
Modalities: Artificial intelligence-based software solutionsDigital health tools for imaging analysis and treatment planning
Industry: Medical Imaging

Partnerships

AriBio (collaboration to support Phase III global trial of AR1001 for Alzheimer’s)

Beyond the preview

Go deeper on Neurophet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurophet.

Explore the full profile